Other
Jun 2024BioPharmGuy labels Synkrino Biotherapeutics defunct based on California filings in this period, but this conflicts with other public sources that still show the company as active.
SourceSynkrino's AI, SATIS is a powerful, unbiased discovery system for…
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Synkrino Biotherapeutics is a YC S18 AI-powered biotech/drug-discovery company built around SATIS, an AI + immunology discovery engine that analyzes patient immune/RNA-seq data to identify disease mechanisms and novel therapeutic targets. Public sources conflict on headquarters and lifecycle status: the company site/YC-style directories point to Berkeley/Oakland, while some third-party directories later label it defunct.
Primary product
SATIS (AI + Immunology Discovery Engine) for drug-target discovery from patient immune data
Founded
2018
Headquarters
Berkeley, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
AI drug discovery / therapeutic discovery and development
Offices
Berkeley, California, United States
Oakland, California, United States
1111 Broadway, Oakland, CA, United States
Business model
biotech R&D
AI-enabled drug-discovery platform
therapeutic target discovery
Funding
Stage
seed
Latest round
Unattributed VC · Aug 2021
Aug 2021 · Blue Bear Ventures
Aug 2018
Mar 2018
People & investors
Work & culture
Product & market
Differentiators
- —Uses patient-derived immune tissue and transcriptomic data rather than generic screening datasets
- —Positions SATIS as an unbiased AI discovery engine for novel drug targets
- —Small, lean team with Y Combinator backing
- —Patent-generating discovery workflow tied to identified targets and repurposing opportunities
Technology
SATIS AI
machine learning
deep learning
graph-based analysis
RNA-seq / transcriptomics
neural networks
Azure cloud
Competitors
Nucleai
Intelligencia
Formation Bio
Biosortia Microbiomics
Evaxion Biotech
Nimbus Therapeutics
Signals & risks
Latest news
aVenture · Mar 2024
Third-party company profile reiterating the AI + immunology discovery thesis, listing the company as founded in 2018 and citing approximately 6 employees as of early 2024.
LinkedIn · Oct 2023
David Ott describes SATIS as a three-stage system using graphs, deep learning, and classification machine learning, and says it has yielded multiple novel targets.
LinkedIn · Oct 2023
Jason Barbour says SATIS identified TWEAK/Fn14 as a driver of UC in non-responding patients and describes a potential repurposing path using existing antibodies.
Company site · Oct 2022
The company homepage’s recent news section links to patent-related updates, including AI transcriptome analysis for drug discovery.
CB Insights · Aug 2021
CB Insights lists funding, investors, patents, and an older product description, including the $120K disclosed funding amount and investors Blue Bear Ventures, Y Combinator, and Fundamental Ventures.
Jobs and careers at Synkrino Biotherapeutics
0 jobs at Synkrino Biotherapeutics
No open positions
Check back later for new openings